Laurel Biotherapeutics

Laurel Biotherapeutics is a private, preclinical biotechnology company developing next-generation antibody therapeutics for cardiovascular disease and related comorbidities. The company is building a precision biologics platform that combines AI-enabled design with immune-derived discovery to create modular single-domain and monoclonal antibody formats. Laurel’s lead disclosed focus is in cardiorenal disease, where it is developing targeted nanobody therapeutics intended to activate the natriuretic peptide pathway and restore protective biological signaling. The broader strategy spans cardiovascular, inflammatory, and metabolic pathways with an emphasis on reducing treatment burden for patients. The company is based in the greater Boston/Cambridge biotech ecosystem and has received support from Mission BioCapital and LabCentral-linked startup programs.